FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376131634> ?p ?o ?g. }

• W4376131634 endingPage "4157" @default.
• W4376131634 startingPage "4144" @default.
• W4376131634 abstract "Ataxia due to an autosomal dominant intronic GAA repeat expansion in FGF14 [GAA-FGF14 ataxia, spinocerebellar ataxia 27B (SCA27B)] has recently been identified as one of the most common genetic late-onset ataxias. We here aimed to characterize its phenotypic profile, natural history progression, and 4-aminopyridine (4-AP) treatment response. We conducted a multi-modal cohort study of 50 GAA-FGF14 patients, comprising in-depth phenotyping, cross-sectional and longitudinal progression data (up to 7 years), MRI findings, serum neurofilament light (sNfL) levels, neuropathology, and 4-AP treatment response data, including a series of n-of-1 treatment studies. GAA-FGF14 ataxia consistently presented as late-onset [60.0 years (53.5-68.5), median (interquartile range)] pancerebellar syndrome, partly combined with afferent sensory deficits (55%) and dysautonomia (28%). Dysautonomia increased with duration while cognitive impairment remained infrequent, even in advanced stages. Cross-sectional and longitudinal assessments consistently indicated mild progression of ataxia [0.29 Scale for the Assessment and Rating of Ataxia (SARA) points/year], not exceeding a moderate disease severity even in advanced stages (maximum SARA score: 18 points). Functional impairment increased relatively slowly (unilateral mobility aids after 8 years in 50% of patients). Corresponding to slow progression and low extra-cerebellar involvement, sNfL was not increased relative to controls. Concurrent second diseases (including progressive supranuclear palsy neuropathology) represented major individual aggravators of disease severity, constituting important caveats for planning future GAA-FGF14 trials. A treatment response to 4-AP with relevance for everyday living was reported by 86% of treated patients. A series of three prospective n-of-1 treatment experiences with on/off design showed marked reduction in daily symptomatic time and symptom severity on 4-AP. Our study characterizes the phenotypic profile, natural history progression, and 4-AP treatment response of GAA-FGF14 ataxia. It paves the way towards large-scale natural history studies and 4-AP treatment trials in this newly discovered, possibly most frequent, and treatable late-onset ataxia." @default.
• W4376131634 created "2023-05-12" @default.
• W4376131634 creator A5004994495 @default.
• W4376131634 creator A5005141795 @default.
• W4376131634 creator A5021963808 @default.
• W4376131634 creator A5022886141 @default.
• W4376131634 creator A5026215755 @default.
• W4376131634 creator A5030179389 @default.
• W4376131634 creator A5031570157 @default.
• W4376131634 creator A5031917279 @default.
• W4376131634 creator A5034475339 @default.
• W4376131634 creator A5034571694 @default.
• W4376131634 creator A5035365079 @default.
• W4376131634 creator A5039670040 @default.
• W4376131634 creator A5056602566 @default.
• W4376131634 creator A5059290458 @default.
• W4376131634 creator A5062512325 @default.
• W4376131634 creator A5068237948 @default.
• W4376131634 creator A5071760235 @default.
• W4376131634 creator A5075596279 @default.
• W4376131634 creator A5076004371 @default.
• W4376131634 creator A5082436384 @default.
• W4376131634 creator A5083821110 @default.
• W4376131634 creator A5091923053 @default.
• W4376131634 date "2023-05-11" @default.
• W4376131634 modified "2023-10-16" @default.
• W4376131634 title "GAA-<i>FGF14</i> ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response" @default.
• W4376131634 cites W1820977370 @default.
• W4376131634 cites W1900218850 @default.
• W4376131634 cites W1951724000 @default.
• W4376131634 cites W1990800058 @default.
• W4376131634 cites W2004039841 @default.
• W4376131634 cites W2030422836 @default.
• W4376131634 cites W2047905051 @default.
• W4376131634 cites W2117257456 @default.
• W4376131634 cites W2132022103 @default.
• W4376131634 cites W2134408741 @default.
• W4376131634 cites W2155296569 @default.
• W4376131634 cites W2155299862 @default.
• W4376131634 cites W2471046935 @default.
• W4376131634 cites W2586615274 @default.
• W4376131634 cites W2743494805 @default.
• W4376131634 cites W2786309249 @default.
• W4376131634 cites W2801410091 @default.
• W4376131634 cites W2891345278 @default.
• W4376131634 cites W3033029449 @default.
• W4376131634 cites W3123380966 @default.
• W4376131634 cites W3200436137 @default.
• W4376131634 cites W3203259389 @default.
• W4376131634 cites W3206241249 @default.
• W4376131634 cites W4224981111 @default.
• W4376131634 cites W4226186081 @default.
• W4376131634 cites W4286685054 @default.
• W4376131634 cites W4292528167 @default.
• W4376131634 cites W4311027012 @default.
• W4376131634 cites W4311448329 @default.
• W4376131634 doi "https://doi.org/10.1093/brain/awad157" @default.
• W4376131634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37165652" @default.
• W4376131634 hasPublicationYear "2023" @default.
• W4376131634 type Work @default.
• W4376131634 citedByCount "10" @default.
• W4376131634 countsByYear W43761316342023 @default.
• W4376131634 crossrefType "journal-article" @default.
• W4376131634 hasAuthorship W4376131634A5004994495 @default.
• W4376131634 hasAuthorship W4376131634A5005141795 @default.
• W4376131634 hasAuthorship W4376131634A5021963808 @default.
• W4376131634 hasAuthorship W4376131634A5022886141 @default.
• W4376131634 hasAuthorship W4376131634A5026215755 @default.
• W4376131634 hasAuthorship W4376131634A5030179389 @default.
• W4376131634 hasAuthorship W4376131634A5031570157 @default.
• W4376131634 hasAuthorship W4376131634A5031917279 @default.
• W4376131634 hasAuthorship W4376131634A5034475339 @default.
• W4376131634 hasAuthorship W4376131634A5034571694 @default.
• W4376131634 hasAuthorship W4376131634A5035365079 @default.
• W4376131634 hasAuthorship W4376131634A5039670040 @default.
• W4376131634 hasAuthorship W4376131634A5056602566 @default.
• W4376131634 hasAuthorship W4376131634A5059290458 @default.
• W4376131634 hasAuthorship W4376131634A5062512325 @default.
• W4376131634 hasAuthorship W4376131634A5068237948 @default.
• W4376131634 hasAuthorship W4376131634A5071760235 @default.
• W4376131634 hasAuthorship W4376131634A5075596279 @default.
• W4376131634 hasAuthorship W4376131634A5076004371 @default.
• W4376131634 hasAuthorship W4376131634A5082436384 @default.
• W4376131634 hasAuthorship W4376131634A5083821110 @default.
• W4376131634 hasAuthorship W4376131634A5091923053 @default.
• W4376131634 hasConcept C118552586 @default.
• W4376131634 hasConcept C126322002 @default.
• W4376131634 hasConcept C15744967 @default.
• W4376131634 hasConcept C2779134260 @default.
• W4376131634 hasConcept C2779500118 @default.
• W4376131634 hasConcept C2780130745 @default.
• W4376131634 hasConcept C2780906641 @default.
• W4376131634 hasConcept C71924100 @default.
• W4376131634 hasConceptScore W4376131634C118552586 @default.
• W4376131634 hasConceptScore W4376131634C126322002 @default.
• W4376131634 hasConceptScore W4376131634C15744967 @default.
• W4376131634 hasConceptScore W4376131634C2779134260 @default.
• W4376131634 hasConceptScore W4376131634C2779500118 @default.

• next